TY - JOUR
T1 - Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase
T2 - Cell line-based assay, kinase panel, molecular docking, and toxicity studies
AU - Elkamhawy, Ahmed
AU - Park, Jung Eun
AU - Cho, Nam Chul
AU - Sim, Taebo
AU - Pae, Ae Nim
AU - Roh, Eun Joo
N1 - Funding Information:
We would like to thank the National Cancer Institute (NCI), Bethesda, MD, USA, for performing the anticancer testing over the cell lines. We also appreciate Dr Haiching Ma from Reaction Biology Corporation for kinase profile screening. The authors have declared no conflict of interest. This research was supported by a grant (NRF-2011-0028676) from the creative/challenging research program of National Research Foundation of Korea.
Publisher Copyright:
© 2015 Korea Institute of Science and Technology. Published by Taylor & Francis.
PY - 2016/1/2
Y1 - 2016/1/2
N2 - Herein, we report compound KST9046, a new agent possessing quinazoline-urea scaffold. Preliminary biological evaluation done by the National Cancer Institute (NCI), USA, showed a great inhibitory effect of KST9046 over the 60 cell-line tumor panel. Accordingly, it was selected for a dose-response assay; a broad spectrum antiproliferative activity with GI50 ranging from 1.3 to 3.9 μM was exerted. To explore a potential kinase inhibitory effect, KST9046 was applied at a single dose of 10 μM against a kinase panel of 347 different enzymes representing >50% of the predicted human protein kinome. Interestingly, selective inhibition of 76% was observed on DDR1 kinase. Further, KST9046 showed an IC50 value of 4.38 μM for DDR1. A molecular docking model presented KST9046 as a potential type III inhibitor for DDR1 kinase with an allosteric mode of interaction, which may offer an explanation for its selectivity. As further investigation, CYP450 assay was carried out for KST9046, it showed a promising toxicity profile against four different isoforms. Based on these findings, KST9046 can be further evaluated as a promising safe new hit for the development of broad spectrum anticancer agents with a selectivity for DDR1 kinase.
AB - Herein, we report compound KST9046, a new agent possessing quinazoline-urea scaffold. Preliminary biological evaluation done by the National Cancer Institute (NCI), USA, showed a great inhibitory effect of KST9046 over the 60 cell-line tumor panel. Accordingly, it was selected for a dose-response assay; a broad spectrum antiproliferative activity with GI50 ranging from 1.3 to 3.9 μM was exerted. To explore a potential kinase inhibitory effect, KST9046 was applied at a single dose of 10 μM against a kinase panel of 347 different enzymes representing >50% of the predicted human protein kinome. Interestingly, selective inhibition of 76% was observed on DDR1 kinase. Further, KST9046 showed an IC50 value of 4.38 μM for DDR1. A molecular docking model presented KST9046 as a potential type III inhibitor for DDR1 kinase with an allosteric mode of interaction, which may offer an explanation for its selectivity. As further investigation, CYP450 assay was carried out for KST9046, it showed a promising toxicity profile against four different isoforms. Based on these findings, KST9046 can be further evaluated as a promising safe new hit for the development of broad spectrum anticancer agents with a selectivity for DDR1 kinase.
KW - CYP450
KW - DDR1 kinase inhibitor
KW - NCI panel
KW - kinase panel
KW - molecular docking
UR - http://www.scopus.com/inward/record.url?scp=84953347439&partnerID=8YFLogxK
U2 - 10.3109/14756366.2015.1004057
DO - 10.3109/14756366.2015.1004057
M3 - Article
C2 - 25807298
AN - SCOPUS:84953347439
SN - 1475-6366
VL - 31
SP - 158
EP - 166
JO - Journal of Enzyme Inhibition and Medicinal Chemistry
JF - Journal of Enzyme Inhibition and Medicinal Chemistry
IS - 1
ER -
